The TGF-β superfamily in dendritic cell biology

Cytokine and Growth Factor Reviews

Volumn 26, Issue 6, 2015, Pages 647-657

  Seeger, Pascal ^a   Musso, Tiziana ^b   Sozzani, Silvano ^a,c  

^a UNIVERSITY OF BRESCIA   (Italy)

^b UNIVERSITY OF TURIN   (Italy)

^c HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

Author keywords

Activin A; Bone morphogenetic protein; Dendritic cells; NK cells; T cells; TGF

Indexed keywords

ACTIVIN A; ACTIVIN RECEPTOR 1; ACTIVIN RECEPTOR LIKE KINASE 1; BONE MORPHOGENETIC PROTEIN 12; BONE MORPHOGENETIC PROTEIN 15; BONE MORPHOGENETIC PROTEIN 2; BONE MORPHOGENETIC PROTEIN 4; BONE MORPHOGENETIC PROTEIN 5; BONE MORPHOGENETIC PROTEIN 6; BONE MORPHOGENETIC PROTEIN 9; GROWTH DIFFERENTIATION FACTOR 10; GROWTH DIFFERENTIATION FACTOR 15; GROWTH DIFFERENTIATION FACTOR 5; GROWTH DIFFERENTIATION FACTOR 6; GROWTH DIFFERENTIATION FACTOR 9; INHIBIN A; INHIBIN B; MUELLERIAN INHIBITING FACTOR; MYELOPID; MYOSTATIN; OSTEOGENIC PROTEIN 1; OSTEOGENIN; RECOMBINANT TRANSFORMING GROWTH FACTOR BETA1; RECOMBINANT TRANSFORMING GROWTH FACTOR BETA2; RECOMBINANT TRANSFORMING GROWTH FACTOR BETA3; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 1; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 2; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 3; UNINDEXED DRUG; ACTIVIN; BONE MORPHOGENETIC PROTEIN; LIGAND;

CELL ACTIVATION; CELL DIFFERENTIATION; CELL FUNCTION; CELL MOTILITY; CYTOLOGY; DENDRITIC CELL; HUMAN; LYMPHOCYTE FUNCTION; NATURAL KILLER CELL; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN TARGETING; REGULATORY MECHANISM; REVIEW; T LYMPHOCYTE; BIOSYNTHESIS; GENE EXPRESSION REGULATION; IMMUNOLOGY; METABOLISM; PHYSIOLOGY; SIGNAL TRANSDUCTION;

ACTIVINS; BONE MORPHOGENETIC PROTEINS; DENDRITIC CELLS; GENE EXPRESSION REGULATION; HUMANS; KILLER CELLS, NATURAL; LIGANDS; SIGNAL TRANSDUCTION; T-LYMPHOCYTES; TRANSFORMING GROWTH FACTOR BETA;

EID: 84949099069     PISSN: 13596101     EISSN: 18790305     Source Type: Journal    
DOI: 10.1016/j.cytogfr.2015.06.002     Document Type: Review

References (148)

1. Banchereau J., Steinman R.M. Dendritic cells and the control of immunity. Nature 1998, 392:245-252.
2. Cerboni S., Gentili M., Manel N. Diversity of pathogen sensors in dendritic cells. Adv. Immunol. 2013, 120:211-237.
3. Steinman R.M., Hemmi H. Dendritic cells: translating innate to adaptive immunity. Curr. Top. Microbiol. Immunol. 2006, 311:17-58.
4. Sozzani S. Dendritic cell trafficking: more than just chemokines. Cytokine Growth Factor Rev. 2005, 16:581-592.
5. Schlitzer A., Ginhoux F. Organization of the mouse and human DC network. Curr. Opin. Immunol. 2014, 26:90-99.
6. Merad M., Sathe P., Helft J., Miller J., Mortha A. The dendritic cell lineage: ontogeny and function of dendritic cells and their subsets in the steady state and the inflamed setting. Annu. Rev. Immunol. 2013, 31:563-604.
7. Dominguez P.M., Ardavin C. Differentiation and function of mouse monocyte-derived dendritic cells in steady state and inflammation. Immunol. Rev. 2010, 234:90-104.
8. Ziegler-Heitbrock L., Ancuta P., Crowe S., et al. Nomenclature of monocytes and dendritic cells in blood. Blood 2010, 116:e74-e80.
9. De Kleer I., Willems F., Lambrecht B., Goriely S. Ontogeny of myeloid cells. Front. Immunol. 2014, 5:423.
10. Boltjes A., van Wijk F. Human dendritic cell functional specialization in steady-state and inflammation. Front. Immunol. 2014, 5:131.
11. Siegal F.P., Kadowaki N., Shodell M., et al. The nature of the principal type 1 interferon-producing cells in human blood. Science 1999, 284:1835-1837.
12. Cella M., Jarrossay D., Facchetti F., et al. Plasmacytoid monocytes migrate to inflamed lymph nodes and produce large amounts of type I interferon. Nat. Med. 1999, 5:919-923.
13. Sozzani S., Vermi W., Del Prete A., Facchetti F. Trafficking properties of plasmacytoid dendritic cells in health and disease. Trends Immunol. 2010, 31:270-277.
14. Romani N., Brunner P.M., Stingl G. Changing views of the role of Langerhans cells. J. Invest. Dermatol. 2012, 132:872-881.
15. Klechevsky E. Human dendritic cells - stars in the skin. Eur. J. Immunol. 2013, 43:3147-3155.
16. Segura E., Amigorena S. Inflammatory dendritic cells in mice and humans. Trends Immunol. 2013, 34:440-445.
17. Lowes M.A., Chamian F., Abello M.V., et al. Increase in TNF-alpha and inducible nitric oxide synthase-expressing dendritic cells in psoriasis and reduction with efalizumab (anti-CD11a). Proc. Natl. Acad. Sci. U. S. A. 2005, 102:19057-19062.
18. Hansel A., Gunther C., Ingwersen J., et al. Human slan (6-sulfo LacNAc) dendritic cells are inflammatory dermal dendritic cells in psoriasis and drive strong TH17/TH1 T-cell responses. J. Allergy Clin. Immunol. 2011, 127(787-794):e781-e789.
19. Walsh K.P., Mills K.H. Dendritic cells and other innate determinants of T helper cell polarisation. Trends Immunol. 2013, 34:521-530.
20. Manicassamy S., Pulendran B. Dendritic cell control of tolerogenic responses. Immunol. Rev. 2011, 241:206-227.
21. Steinman R.M., Hawiger D., Nussenzweig M.C. Tolerogenic dendritic cells. Annu. Rev. Immunol. 2003, 21:685-711.
22. Lutz M.B., Schuler G. Immature, semi-mature and fully mature dendritic cells: which signals induce tolerance or immunity?. Trends Immunol. 2002, 23:445-449.
23. Probst H.C., Muth S., Schild H. Regulation of the tolerogenic function of steady-state DCs. Eur. J. Immunol. 2014, 44:927-933.
24. Hopp A.K., Rupp A., Lukacs-Kornek V. Self-antigen presentation by dendritic cells in autoimmunity. Front. Immunol. 2014, 5:55.
25. Mellor A.L., Munn D.H. IDO expression by dendritic cells: tolerance and tryptophan catabolism. Nat. Rev. Immunol. 2004, 4:762-774.
26. Moreau A., Hill M., Thebault P., et al. Tolerogenic dendritic cells actively inhibit T cells through heme oxygenase-1 in rodents and in nonhuman primates. FASEB J. 2009, 23:3070-3077.
27. Wakefield L.M., Hill C.S. Beyond TGFbeta: roles of other TGFbeta superfamily members in cancer. Nat. Rev. Cancer 2013, 13:328-341.
28. Harrison C.A., Al-Musawi S.L., Walton K.L. Prodomains regulate the synthesis, extracellular localisation and activity of TGF-beta superfamily ligands. Growth Factors 2011, 29:174-186.
29. Li M.O., Wan Y.Y., Sanjabi S., Robertson A.K., Flavell R.A. Transforming growth factor-beta regulation of immune responses. Annu. Rev. Immunol. 2006, 24:99-146.
30. Weiss A., Attisano L. The TGFbeta superfamily signaling pathway. Wiley Interdiscip. Rev. Dev. Biol. 2013, 2:47-63.
31. Moustakas A., Heldin C.H. Non-Smad TGF-beta signals. J. Cell Sci. 2005, 118:3573-3584.
32. Hedger M.P., Winnall W.R., Phillips D.J., de Kretser D.M. The regulation and functions of activin and follistatin in inflammation and immunity. Vitam. Horm. 2011, 85:255-297.
33. Neuzillet C., Tijeras-Raballand A., Cohen R., et al. Targeting the TGFbeta pathway for cancer therapy. Pharmacol. Ther. 2014, 147:22-31.
34. Worthington J.J., Fenton T.M., Czajkowska B.I., Klementowicz J.E., Travis M.A. Regulation of TGFbeta in the immune system: an emerging role for integrins and dendritic cells. Immunobiology 2012, 217:1259-1265.
35. Shull M.M., Ormsby I., Kier A.B., et al. Targeted disruption of the mouse transforming growth factor-beta 1 gene results in multifocal inflammatory disease. Nature 1992, 359:693-699.
36. Kulkarni A.B., Huh C.G., Becker D., et al. Transforming growth factor beta 1 null mutation in mice causes excessive inflammatory response and early death. Proc. Natl. Acad. Sci. U. S. A. 1993, 90:770-774.
37. Travis M.A., Sheppard D. TGF-beta activation and function in immunity. Annu. Rev. Immunol. 2014, 32:51-82.
38. Kis-Toth K., Bacskai I., Gogolak P., Mazlo A., Szatmari I., Rajnavolgyi E. Monocyte-derived dendritic cell subpopulations use different types of matrix metalloproteinases inhibited by GM6001. Immunobiology 2013, 218:1361-1369.
39. Gawden-Bone C., Zhou Z., King E., Prescott A., Watts C., Lucocq J. Dendritic cell podosomes are protrusive and invade the extracellular matrix using metalloproteinase MMP-14. J. Cell Sci. 2010, 123:1427-1437.
40. Gandhi N.B., Su Z., Zhang X., et al. Dendritic cell-derived thrombospondin-1 is critical for the generation of the ocular surface Th17 response to desiccating stress. J. Leukoc. Biol. 2013, 94:1293-1301.
41. Travis M.A., Reizis B., Melton A.C., et al. Loss of integrin alpha(v)beta8 on dendritic cells causes autoimmunity and colitis in mice. Nature 2007, 449:361-365.
42. Worthington J.J., Czajkowska B.I., Melton A.C., Travis M.A. Intestinal dendritic cells specialize to activate transforming growth factor-beta and induce Foxp3+ regulatory T cells via integrin alphavbeta8. Gastroenterology 2011, 141:1802-1812.
43. Kudo M., Melton A.C., Chen C., et al. IL-17A produced by alphabeta T cells drives airway hyper-responsiveness in mice and enhances mouse and human airway smooth muscle contraction. Nat. Med. 2012, 18:547-554.
44. Melton A.C., Bailey-Bucktrout S.L., Travis M.A., Fife B.T., Bluestone J.A., Sheppard D. Expression of alphavbeta8 integrin on dendritic cells regulates Th17 cell development and experimental autoimmune encephalomyelitis in mice. J. Clin. Invest. 2010, 120:4436-4444.
45. Acharya M., Mukhopadhyay S., Paidassi H., et al. αv Integrin expression by DCs is required for Th17 cell differentiation and development of experimental autoimmune encephalomyelitis in mice. J. Clin. Invest. 2010, 120:4445-4452.
46. Liu K., Nussenzweig M.C. Origin and development of dendritic cells. Immunol. Rev. 2010, 234:45-54.
47. Schmid M.A., Kingston D., Boddupalli S., Manz M.G. Instructive cytokine signals in dendritic cell lineage commitment. Immunol. Rev. 2010, 234:32-44.
48. Sere K.M., Lin Q., Felker P., et al. Dendritic cell lineage commitment is instructed by distinct cytokine signals. Eur. J. Cell Biol. 2012, 91:515-523.
49. Felker P., Sere K., Lin Q., et al. TGF-beta1 accelerates dendritic cell differentiation from common dendritic cell progenitors and directs subset specification toward conventional dendritic cells. J. Immunol. 2010, 185:5326-5335.
50. Sere K., Felker P., Hieronymus T., Zenke M. TGFbeta1 microenvironment determines dendritic cell development. Oncoimmunology 2013, 2:e23083.
51. Borkowski T.A., Letterio J.J., Farr A.G., Udey M.C. A role for endogenous transforming growth factor beta 1 in Langerhans cell biology: the skin of transforming growth factor beta 1 null mice is devoid of epidermal Langerhans cells. J. Exp. Med. 1996, 184:2417-2422.
52. Strobl H., Riedl E., Scheinecker C., et al. TGF-beta 1 promotes in vitro development of dendritic cells from CD34+ hemopoietic progenitors. J. Immunol. 1996, 157:1499-1507.
53. Strobl H., Knapp W. TGF-beta1 regulation of dendritic cells. Microbes Infect. 1999, 1:1283-1290.
54. Geissmann F., Prost C., Monnet J.P., Dy M., Brousse N., Hermine O. Transforming growth factor beta1, in the presence of granulocyte/macrophage colony-stimulating factor and interleukin 4, induces differentiation of human peripheral blood monocytes into dendritic Langerhans cells. J. Exp. Med. 1998, 187:961-966.
55. Zahner S.P., Kel J.M., Martina C.A., Brouwers-Haspels I., van Roon M.A., Clausen B.E. Conditional deletion of TGF-betaR1 using Langerin-Cre mice results in Langerhans cell deficiency and reduced contact hypersensitivity. J. Immunol. 2011, 187:5069-5076.
56. Kaplan D.H., Li M.O., Jenison M.C., Shlomchik W.D., Flavell R.A., Shlomchik M.J. Autocrine/paracrine TGFbeta1 is required for the development of epidermal Langerhans cells. J. Exp. Med. 2007, 204:2545-2552.
57. Bobr A., Igyarto B.Z., Haley K.M., Li M.O., Flavell R.A., Kaplan D.H. Autocrine/paracrine TGF-beta1 inhibits Langerhans cell migration. Proc. Natl. Acad. Sci. U. S. A. 2012, 109:10492-10497.
58. Kel J.M., Girard-Madoux M.J., Reizis B., Clausen B.E. TGF-beta is required to maintain the pool of immature Langerhans cells in the epidermis. J. Immunol. 2010, 185:3248-3255.
59. Hacker C., Kirsch R.D., Ju X.S., et al. Transcriptional profiling identifies Id2 function in dendritic cell development. Nat. Immunol. 2003, 4:380-386.
60. Fainaru O., Woolf E., Lotem J., et al. Runx3 regulates mouse TGF-beta-mediated dendritic cell function and its absence results in airway inflammation. EMBO J. 2004, 23:969-979.
61. Li A.G., Lu S.L., Han G., Hoot K.E., Wang X.J. Role of TGFbeta in skin inflammation and carcinogenesis. Mol. Carcinog. 2006, 45:389-396.
62. Schuster C., Vaculik C., Fiala C., et al. HLA-DR+ leukocytes acquire CD1 antigens in embryonic and fetal human skin and contain functional antigen-presenting cells. J. Exp. Med. 2009, 206:169-181.
63. Yasmin N., Bauer T., Modak M., et al. Identification of bone morphogenetic protein 7 (BMP7) as an instructive factor for human epidermal Langerhans cell differentiation. J. Exp. Med. 2013, 210:2597-2610.
64. Merad M., Ginhoux F., Collin M. Origin, homeostasis and function of Langerhans cells and other langerin-expressing dendritic cells. Nat. Rev. Immunol. 2008, 8:935-947.
65. Milne P., Bigley V., Gunawan M., Haniffa M., Collin M. CD1c+ blood dendritic cells have Langerhans cell potential. Blood 2014.
66. Martinez-Cingolani C., Grandclaudon M., Jeanmougin M., Jouve M., Zollinger R., Soumelis V. Human blood BDCA-1 dendritic cells differentiate into Langerhans-like cells with thymic stromal lymphopoietin and TGF-beta. Blood 2014, 124:2411-2420.
67. Van Pottelberge G.R., Bracke K.R., Demedts I.K., et al. Selective accumulation of Langerhans-type dendritic cells in small airways of patients with COPD. Respir. Res. 2010, 11:35.
68. Musso T., Scutera S., Vermi W., et al. Activin A induces Langerhans cell differentiation in vitro and in human skin explants. PLoS ONE 2008, 3:e3271.
69. Antsiferova M., Huber M., Meyer M., et al. Activin enhances skin tumourigenesis and malignant progression by inducing a pro-tumourigenic immune cell response. Nat. Commun. 2011, 2:576.
70. Stoitzner P., Stossel H., Wankell M., et al. Langerhans cells are strongly reduced in the skin of transgenic mice overexpressing follistatin in the epidermis. Eur. J. Cell Biol. 2005, 84:733-741.
71. Robson N.C., Phillips D.J., McAlpine T., et al. Activin-A: a novel dendritic cell-derived cytokine that potently attenuates CD40 ligand-specific cytokine and chemokine production. Blood 2008, 111:2733-2743.
72. Martinez V.G., Hernandez-Lopez C., Valencia J., et al. The canonical BMP signaling pathway is involved in human monocyte-derived dendritic cell maturation. Immunol. Cell Biol. 2011, 89:610-618.
73. Ramalingam R., Larmonier C.B., Thurston R.D., et al. Dendritic cell-specific disruption of TGF-beta receptor II leads to altered regulatory T cell phenotype and spontaneous multiorgan autoimmunity. J. Immunol. 2012, 189:3878-3893.
74. Lievens D., Habets K.L., Robertson A.K., et al. Abrogated transforming growth factor beta receptor II (TGFbetaRII) signalling in dendritic cells promotes immune reactivity of T cells resulting in enhanced atherosclerosis. Eur. Heart J. 2013, 34:3717-3727.
75. Laouar Y., Town T., Jeng D., et al. TGF-beta signaling in dendritic cells is a prerequisite for the control of autoimmune encephalomyelitis. Proc. Natl. Acad. Sci. U. S. A. 2008, 105:10865-10870.
76. Flavell R.A., Sanjabi S., Wrzesinski S.H., Licona-Limon P. The polarization of immune cells in the tumour environment by TGFbeta. Nat. Rev. Immunol. 2010, 10:554-567.
77. Fainaru O., Shay T., Hantisteanu S., Goldenberg D., Domany E., Groner Y. TGFbeta-dependent gene expression profile during maturation of dendritic cells. Genes Immunol. 2007, 8:239-244.
78. Bonnefoy F., Couturier M., Clauzon A., et al. TGF-beta-exposed plasmacytoid dendritic cells participate in Th17 commitment. J. Immunol. 2011, 186:6157-6164.
79. Ohtani T., Mizuashi M., Nakagawa S., et al. TGF-beta1 dampens the susceptibility of dendritic cells to environmental stimulation, leading to the requirement for danger signals for activation. Immunology 2009, 126:485-499.
80. Geissmann F., Revy P., Regnault A., et al. TGF-beta 1 prevents the noncognate maturation of human dendritic Langerhans cells. J. Immunol. 1999, 162:4567-4575.
81. Brown R.D., Pope B., Murray A., et al. Dendritic cells from patients with myeloma are numerically normal but functionally defective as they fail to up-regulate CD80 (B7-1) expression after huCD40LT stimulation because of inhibition by transforming growth factor-beta1 and interleukin-10. Blood 2001, 98:2992-2998.
82. Dumitriu I.E., Dunbar D.R., Howie S.E., Sethi T., Gregory C.D. Human dendritic cells produce TGF-beta 1 under the influence of lung carcinoma cells and prime the differentiation of CD4+ CD25+ Foxp3+ regulatory T cells. J. Immunol. 2009, 182:2795-2807.
83. Belladonna M.L., Volpi C., Bianchi R., et al. Cutting edge: autocrine TGF-beta sustains default tolerogenesis by IDO-competent dendritic cells. J. Immunol. 2008, 181:5194-5198.
84. Yan Y., Zhang G.X., Gran B., et al. IDO upregulates regulatory T cells via tryptophan catabolite and suppresses encephalitogenic T cell responses in experimental autoimmune encephalomyelitis. J. Immunol. 2010, 185:5953-5961.
85. Fallarino F., Grohmann U., Puccetti P. Indoleamine 2,3-dioxygenase: from catalyst to signaling function. Eur. J. Immunol. 2012, 42:1932-1937.
86. Pallotta M.T., Orabona C., Volpi C., et al. Indoleamine 2,3-dioxygenase is a signaling protein in long-term tolerance by dendritic cells. Nat. Immunol. 2011, 12:870-878.
87. Seeger P., Bosisio D., Parolini S., et al. Activin A as a mediator of NK-dendritic cell functional interactions. J. Immunol. 2014, 192:1241-1248.
88. Scutera S., Riboldi E., Daniele R., et al. Production and function of activin A in human dendritic cells. Eur. Cytokine Netw. 2008, 19:60-68.
89. Zhou Z., Li W., Song Y., et al. Growth differentiation factor-15 suppresses maturation and function of dendritic cells and inhibits tumor-specific immune response. PLOS ONE 2013, 8:e78618.
90. Unsicker K., Spittau B., Krieglstein K. The multiple facets of the TGF-beta family cytokine growth/differentiation factor-15/macrophage inhibitory cytokine-1. Cytokine Growth Factor Rev. 2013, 24:373-384.
91. Segerer S.E., Muller N., Brandt J., et al. The glycoprotein-hormones activin A and inhibin A interfere with dendritic cell maturation. Reprod. Biol. Endocrinol. 2008, 6:17.
92. Martinez V.G., Hidalgo L., Valencia J., et al. Autocrine activation of canonical BMP signaling regulates PD-L1 and PD-L2 expression in human dendritic cells. Eur. J. Immunol. 2014, 44:1031-1038.
93. Ogata M., Zhang Y., Wang Y., et al. Chemotactic response toward chemokines and its regulation by transforming growth factor-beta1 of murine bone marrow hematopoietic progenitor cell-derived different subset of dendritic cells. Blood 1999, 93:3225-3232.
94. Salogni L., Musso T., Bosisio D., et al. Activin A induces dendritic cell migration through the polarized release of CXC chemokine ligands 12 and 14. Blood 2009, 113:5848-5856.
95. Sato K., Kawasaki H., Nagayama H., et al. TGF-beta 1 reciprocally controls chemotaxis of human peripheral blood monocyte-derived dendritic cells via chemokine receptors. J. Immunol. 2000, 164:2285-2295.
96. Imai K., Minamiya Y., Koyota S., et al. Inhibition of dendritic cell migration by transforming growth factor-beta1 increases tumor-draining lymph node metastasis. J. Exp. Clin. Cancer Res. 2012, 31:3.
97. Mohammed J., Gunderson A.J., Khong H.H., Koubek R.D., Udey M.C., Glick A.B. TGFbeta1 overexpression by keratinocytes alters skin dendritic cell homeostasis and enhances contact hypersensitivity. J. Invest. Dermatol. 2013, 133:135-143.
98. Fumagalli M., Musso T., Vermi W., et al. Imbalance between activin A and follistatin drives postburn hypertrophic scar formation in human skin. Exp. Dermatol. 2007, 16:600-610.
99. Vittorakis S., Samitas K., Tousa S., et al. Circulating conventional and plasmacytoid dendritic cell subsets display distinct kinetics during in vivo repeated allergen skin challenges in atopic subjects. Biomed. Res. Int. 2014, 2014:231036.
100. Gandhi R., Anderson D.E., Weiner H.L. Cutting edge: immature human dendritic cells express latency-associated peptide and inhibit T cell activation in a TGF-beta-dependent manner. J. Immunol. 2007, 178:4017-4021.
101. Kushwah R., Wu J., Oliver J.R., et al. Uptake of apoptotic DC converts immature DC into tolerogenic DC that induce differentiation of Foxp3+ Treg. Eur. J. Immunol. 2010, 40:1022-1035.
102. Yamazaki S., Dudziak D., Heidkamp G.F., et al. CD8+ CD205+ splenic dendritic cells are specialized to induce Foxp3+ regulatory T cells. J. Immunol. 2008, 181:6923-6933.
103. Aliahmadi E., Gramlich R., Grutzkau A., et al. TLR2-activated human Langerhans cells promote Th17 polarization via IL-1beta, TGF-beta and IL-23. Eur. J. Immunol. 2009, 39:1221-1230.
104. Morelli A.E., Zahorchak A.F., Larregina A.T., et al. Cytokine production by mouse myeloid dendritic cells in relation to differentiation and terminal maturation induced by lipopolysaccharide or CD40 ligation. Blood 2001, 98:1512-1523.
105. Stary G., Klein I., Bauer W., et al. Glucocorticosteroids modify Langerhans cells to produce TGF-beta and expand regulatory T cells. J. Immunol. 2011, 186:103-112.
106. Perruche S., Zhang P., Liu Y., Saas P., Bluestone J.A., Chen W. CD3-specific antibody-induced immune tolerance involves transforming growth factor-beta from phagocytes digesting apoptotic T cells. Nat. Med. 2008, 14:528-535.
107. Ravishankar B., Liu H., Shinde R., et al. Tolerance to apoptotic cells is regulated by indoleamine 2,3-dioxygenase. Proc. Natl. Acad. Sci. U. S. A. 2012, 109:3909-3914.
108. Kushwah R., Oliver J.R., Zhang J., Siminovitch K.A., Hu J. Apoptotic dendritic cells induce tolerance in mice through suppression of dendritic cell maturation and induction of antigen-specific regulatory T cells. J. Immunol. 2009, 183:7104-7118.
109. Huang G., Wang Y., Chi H. Control of T cell fates and immune tolerance by p38alpha signaling in mucosal CD103+ dendritic cells. J. Immunol. 2013, 191:650-659.
110. Sun C.M., Hall J.A., Blank R.B., et al. Small intestine lamina propria dendritic cells promote de novo generation of Foxp3 T reg cells via retinoic acid. J. Exp. Med. 2007, 204:1775-1785.
111. Coombes J.L., Siddiqui K.R., Arancibia-Carcamo C.V., et al. A functionally specialized population of mucosal CD103+ DCs induces Foxp3+ regulatory T cells via a TGF-beta and retinoic acid-dependent mechanism. J. Exp. Med. 2007, 204:1757-1764.
112. Yu C.I., Becker C., Wang Y., et al. Human CD1c+ dendritic cells drive the differentiation of CD103+ CD8+ mucosal effector T cells via the cytokine TGF-beta. Immunity 2013, 38:818-830.
113. Chen C.H., Seguin-Devaux C., Burke N.A., et al. Transforming growth factor beta blocks Tec kinase phosphorylation, Ca2+ influx, and NFATc translocation causing inhibition of T cell differentiation. J. Exp. Med. 2003, 197:1689-1699.
114. Gorelik L., Fields P.E., Flavell R.A. Cutting edge: TGF-beta inhibits Th type 2 development through inhibition of GATA-3 expression. J. Immunol. 2000, 165:4773-4777.
115. Neurath M.F., Weigmann B., Finotto S., et al. The transcription factor T-bet regulates mucosal T cell activation in experimental colitis and Crohn's disease. J. Exp. Med. 2002, 195:1129-1143.
116. Gordon J.R., Li F., Nayyar A., Xiang J., Zhang X. CD8 alpha+, but not CD8 alpha-, dendritic cells tolerize Th2 responses via contact-dependent and -independent mechanisms, and reverse airway hyperresponsiveness, Th2, and eosinophil responses in a mouse model of asthma. J. Immunol. 2005, 175:1516-1522.
117. Sakaguchi S., Yamaguchi T., Nomura T., Ono M. Regulatory T cells and immune tolerance. Cell 2008, 133:775-787.
118. Kim J.M., Rasmussen J.P., Rudensky A.Y. Regulatory T cells prevent catastrophic autoimmunity throughout the lifespan of mice. Nat. Immunol. 2007, 8:191-197.
119. Oh S.A., Li M.O. TGF-beta: guardian of T cell function. J. Immunol. 2013, 191:3973-3979.
120. Zheng Y., Josefowicz S., Chaudhry A., Peng X.P., Forbush K., Rudensky A.Y. Role of conserved non-coding DNA elements in the Foxp3 gene in regulatory T-cell fate. Nature 2010, 463:808-812.
121. Tone Y., Furuuchi K., Kojima Y., Tykocinski M.L., Greene M.I., Tone M. Smad3 and NFAT cooperate to induce Foxp3 expression through its enhancer. Nat. Immunol. 2008, 9:194-202.
122. Xiao S., Jin H., Korn T., et al. Retinoic acid increases Foxp3+ regulatory T cells and inhibits development of Th17 cells by enhancing TGF-beta-driven Smad3 signaling and inhibiting IL-6 and IL-23 receptor expression. J. Immunol. 2008, 181:2277-2284.
123. Benson M.J., Pino-Lagos K., Rosemblatt M., Noelle R.J. All-trans retinoic acid mediates enhanced T reg cell growth, differentiation, and gut homing in the face of high levels of co-stimulation. J. Exp. Med. 2007, 204:1765-1774.
124. Khare A., Krishnamoorthy N., Oriss T.B., Fei M., Ray P., Ray A. Cutting edge: inhaled antigen upregulates retinaldehyde dehydrogenase in lung CD103+ but not plasmacytoid dendritic cells to induce Foxp3 de novo in CD4+ T cells and promote airway tolerance. J. Immunol. 2013, 191:25-29.
125. Wang L., Pino-Lagos K., de Vries V.C., Guleria I., Sayegh M.H., Noelle R.J. Programmed death 1 ligand signaling regulates the generation of adaptive Foxp3+ CD4+ regulatory T cells. Proc. Natl. Acad. Sci. U. S. A. 2008, 105:9331-9336.
126. Semitekolou M., Alissafi T., Aggelakopoulou M., et al. Activin-A induces regulatory T cells that suppress T helper cell immune responses and protect from allergic airway disease. J. Exp. Med. 2009, 206:1769-1785.
127. Huber S., Stahl F.R., Schrader J., et al. Activin a promotes the TGF-beta-induced conversion of CD4+CD25- T cells into Foxp3+ induced regulatory T cells. J. Immunol. 2009, 182:4633-4640.
128. Lu L., Ma J., Wang X., et al. Synergistic effect of TGF-beta superfamily members on the induction of Foxp3+ Treg. Eur. J. Immunol. 2010, 40:142-152.
129. Huber S., Schramm C. Role of activin A in the induction of Foxp3+ and Foxp3- CD4+ regulatory T cells. Crit. Rev. Immunol. 2011, 31:53-60.
130. Sozzani S., Musso T. The yin and yang of Activin A. Blood 2011, 117:5013-5015.
131. Hardy C.L., O'Connor A.E., Yao J., et al. Follistatin is a candidate endogenous negative regulator of activin A in experimental allergic asthma. Clin. Exp. Allergy 2006, 36:941-950.
132. Ogawa K., Funaba M. Activin in humoral immune responses. Vitam. Horm. 2011, 85:235-253.
133. Noack M., Miossec P. Th17 and regulatory T cell balance in autoimmune and inflammatory diseases. Autoimmun. Rev. 2014, 13:668-677.
134. Veldhoen M., Hocking R.J., Flavell R.A., Stockinger B. Signals mediated by transforming growth factor-beta initiate autoimmune encephalomyelitis, but chronic inflammation is needed to sustain disease. Nat. Immunol. 2006, 7:1151-1156.
135. Bettelli E., Carrier Y., Gao W., et al. Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature 2006, 441:235-238.
136. Gutcher I., Donkor M.K., Ma Q., Rudensky A.Y., Flavell R.A., Li M.O. Autocrine transforming growth factor-beta1 promotes in vivo Th17 cell differentiation. Immunity 2011, 34:396-408.
137. He R., Oyoshi M.K., Jin H., Geha R.S. Epicutaneous antigen exposure induces a Th17 response that drives airway inflammation after inhalation challenge. Proc. Natl. Acad. Sci. U. S. A. 2007, 104:15817-15822.
138. Kimura A., Naka T., Kishimoto T. IL-6-dependent and -independent pathways in the development of interleukin 17-producing T helper cells. Proc. Natl. Acad. Sci. U. S. A. 2007, 104:12099-12104.
139. Torchinsky M.B., Garaude J., Martin A.P., Blander J.M. Innate immune recognition of infected apoptotic cells directs T(H)17 cell differentiation. Nature 2009, 458:78-82.
140. Xu L., Wang C., Zhou Y., Ren T., Wen Z. CpG oligonucleotides induce the differentiation of CD4(+)Th17 cells by triggering plasmacytoid dendritic cells in adoptively cell transfer immunotherapy. Immunol. Lett. 2012, 142:55-63.
141. Robson N.C., Hidalgo L., McAlpine T., et al. Optimal effector functions in human natural killer cells rely upon autocrine bone morphogenetic protein signaling. Cancer Res. 2014, 74:5019-5031.
142. Robson N.C., Wei H., McAlpine T., Kirkpatrick N., Cebon J., Maraskovsky E. Activin-A attenuates several human natural killer cell functions. Blood 2009, 113:3218-3225.
143. Bellone G., Aste-Amezaga M., Trinchieri G., Rodeck U. Regulation of NK cell functions by TGF-beta 1. J. Immunol. 1995, 155:1066-1073.
144. Castriconi R., Dondero A., Bellora F., et al. Neuroblastoma-derived TGF-beta1 modulates the chemokine receptor repertoire of human resting NK cells. J. Immunol. 2013, 190:5321-5328.
145. Eriksson M., Meadows S.K., Wira C.R., Sentman C.L. Unique phenotype of human uterine NK cells and their regulation by endogenous TGF-beta. J. Leukoc. Biol. 2004, 76:667-675.
146. Trotta R., Dal Col J., Yu J., et al. TGF-beta utilizes SMAD3 to inhibit CD16-mediated IFN-gamma production and antibody-dependent cellular cytotoxicity in human NK cells. J. Immunol. 2008, 181:3784-3792.
147. Sarhan D., Palma M., Mao Y., et al. Dendritic cell regulation of NK-cell responses involves lymphotoxin-alpha, IL-12 and TGF-beta. Eur. J. Immunol. 2015.
148. Mueller T.D., Nickel J. Promiscuity and specificity in BMP receptor activation. FEBS Lett. 2012, 586:1846-1859.